t e c h n i c a l r e p o r t s
Although antiretroviral therapy can suppress HIV-1 infection to undetectable levels of plasma viremia, integrated latent HIV-1 genomes that encode replication-competent virus persist in resting CD4 + T cells. This latent HIV-1 reservoir represents a major barrier to a cure. Currently, there are substantial efforts to identify therapeutic approaches that will eliminate or reduce the size of this latent HIV-1 reservoir. In this regard, a sensitive assay that can accurately and rapidly quantify inducible, replication-competent latent HIV-1 from resting CD4 + T cells is essential for HIV-1 eradication studies. Here we describe a reporter cell-based assay to quantify inducible, replicationcompetent latent HIV-1. This assay has several advantages over existing technology in that it (i) is sensitive; (ii) requires only a small blood volume; (iii) is faster, less labor intensive, and less expensive; and (iv) can be readily adapted into a highthroughput format. Using this assay, we show that the size of the inducible latent HIV-1 reservoir in aviremic participants on therapy is approximately 70-fold larger than previous estimates.
The latent HIV-1 reservoir in resting CD4 + (rCD4 + ) T cells is an obstacle to the eradication of HIV-1 infection. This reservoir is small, consisting of approximately 1-10 infectious units per million cells [1] [2] [3] . Therefore, it is crucial to develop assays that can reproducibly quantify the reservoir size-and changes therein-in participants enrolled in curative intervention strategies. So far, several assays for measuring cell-associated HIV-1 DNA and RNA have been developed [4] [5] [6] [7] [8] . However, their clinical utility is unclear, because the majority of integrated HIV-1 DNA is replication defective [9] [10] [11] , and measurement of viral mRNA expression might not reflect the amount of replicationcompetent virus. For this reason, the quantitative viral outgrowth assay (Q-VOA) 3, 12 , which quantifies inducible, replication-competent HIV-1 from rCD4 + T cells, is considered to be the gold standard. However, the Q-VOA might provide a minimal estimate of the size of the latent HIV-1 reservoir because it only detects a fraction of the total integrated pool of replication-competent HIV-1, perhaps in part due to stochastic reactivation of the latent reservoir following maximum T cell activation 9, 10, 13 . Nevertheless, underestimating the size of the latent reservoir in rCD4 + T cells could result in the misconception that an individual with HIV-1 infection is cured, when in fact they are not. Additionally, the Q-VOA requires a large volume of blood (120-180 ml) 13 , is labor intensive, time consuming, and expensive. As such, the development of a rapid, high-throughput, sensitive, and validated assay is important for clinical studies that are evaluating cure strategies, and for researchers who are trying to identify new latency-reversing agents and to characterize the latent reservoir ex vivo. In this report, we describe the development of a sensitive assay, termed TZA, to quantify inducible, replication-competent HIV-1. This assay utilizes the TZM-bl cell line, which stably expresses the HIV-1 receptor CD4, and co-receptors CCR5 and CXCR4, and it carries an integrated copy of the β-galactosidase (β-gal) gene under control of an HIV-1 long terminal repeat (LTR) promoter. Using this assay, we show that the size of the inducible latent HIV-1 reservoir in aviremic individuals on antiretroviral therapy (ART) is approximately 70-fold larger than previous estimates.
RESULTS

Sensitivity of TZM-bl cells to infection by replicationcompetent HIV-1
To establish the sensitivity of TZM-bl cells to HIV-1 infection, we first serially diluted CD4 + T lymphocytes from uninfected donors-which were acutely infected with the clinical HIV-1 isolate 017-along with uninfected, CD8 + T cell-depleted peripheral blood mononuclear cells (PBMCs), and we added 1 × 10 5 cells from each serial dilution to 5 × 10 4 TZM-bl cells in a 96-well plate. β-gal activity was measured by chemiluminescence 48 h later. We found that the TZM-bl cells reproducibly detected infection with a sensitivity down to 0.3 infected cells/10 6 PBMCs (Fig. 1a) . We also treated the latently HIV-1-infected human T cell line ACH-2 (ref. 14) with 100-nM phorbol 12-myristate 13-acetate (PMA), serially diluted ACH-2 cells with uninfected CD8 + T cell-depleted PBMCs, and similarly, added them to TZM-bl cells. We could detect at least 0.1 infectious HIV-1-producing ACH-2 cells/10 6 CD8 + T cell-depleted PBMCs (Fig. 1b) . Next, to determine whether the signal detected by TZM-bl cells was due to replication-competent HIV-1, TZM-bl cells were infected with serially diluted R5-tropic HIV-1 BaL t e c h n i c a l r e p o r t s 8 8 6 VOLUME 23 | NUMBER 7 | JULY 2017 nature medicine (a subtype of B, laboratory strain of HIV-1 isolated from the lung of an infant) with a known infectivity titer (tissue-culture infectivity dose (TCID 50 ) of 10 0 -10 6 ). β-gal activity was measured 48 h postinfection, and virus production was measured following the addition of CD8 + T cell-depleted PBMCs to TZM-bl cells 2 d postinfection, and extracellular virion-associated HIV-1 RNA was quantified 10 d later. Therefore, the HIV-1 RNA measured here reflected the level of expanded viral RNA from HIV-1 BaL -infected TZM-bl cells. We found strong correlations between β-gal activity and TCID 50 (r = 0.76; P = 0.01) and between β-gal activity and extracellular virus production (r = 0.97; P = 0.0003) (Fig. 1c,d) . Next, we assessed the sensitivity of the β-gal and virus-production signals as a function of low TCID 50 values (10 −3 -10 1 ). We observed that the response for the β-gal activity extended as far as 0.001 TCID 50 , but only as far as 1.0 TCID 50 for virus production (Fig. 1e) . These data highlight that the β-gal signal is more sensitive than measurement of virus production, as assessed by extracellular virion-associated HIV-1 RNA.
Sensitivity of TZM-bl cells to infection by replication-defective HIV-1
To ascertain whether replication-defective HIV-1 particles were detected with the TZM-bl assay, we measured β-gal activity following their incubation with three different clones of the latently HIV-1-infected J-Lat Jurkat T cell line 15 . Each J-Lat clone contains a full-length, integrated HIV-1 genome that expresses green fluorescent protein upon activation, and generates defective virions owing to a frameshift mutation in the HIV-1 env gene. Additionally, each of the J-Lat clones produces a different amount of extracellular virus particles after stimulation with 100-nM PMA (Supplementary Table 1 ).
Our data show that none of the J-Lat clones produced any signal in the TZM-bl cells (Fig. 2a) . We also evaluated the chronically infected T cell line 8E5, which contains a single, integrated copy of proviral X4-tropic HIV-1 LAV (lymphadenopathy-associated virus) DNA and produces defective virus particles that lack reverse transcriptase 16 . Our data (Fig. 2b) show that no positive β-gal signal in the TZM-bl cells was detected relative to the control after the addition of up to 4,000 8E5 cells (which produce 8,606 pg/ml of viral p24 protein), although at higher 8E5 cell concentrations, we noted β-gal activity. By contrast, as indicated in Figure 1a ,b, we can detect a positive signal by using less than 1 cell infected with replication-competent HIV-1 per 10 6 cells. Finally, we evaluated the ability of a full-length, replication-defective clone of the X4-tropic HIV-1 LAI laboratory strain that harbors the inactivating L289K mutation in the reverse-transcriptaseencoding gene 17 to infect TZM-bl cells. In comparison to wild-type HIV-1, the mutant virus did not induce any β-gal activity in TZM-bl cells, even when 1,000 pg of p24-equivalent virus was added to the cells (Fig. 2c) . Collectively, these data demonstrate that TZM-bl cells are insensitive to replication-defective virus particles containing mutations in env or reverse transcriptase.
Quantification of inducible, replication-competent HIV-1 from rCD4 + T cells purified from individuals with HIV-1 infection
We next developed a strategy for quantifying inducible, replicationcompetent HIV-1 from rCD4 + T cells purified from aviremic individuals with HIV-1 infection who were on suppressive combination antiretroviral therapy (cART). This process involved (i) the induction of latent virus using anti-CD3/CD28 monoclonal antibody (mAb)-coated microbeads; and (ii) quantification of the induced, replication-competent HIV-1 in TZM-bl cells (Fig. 3a) . Blood was obtained from 15 participants who were enrolled at the Pittsburgh clinical site were stimulated with PHA, serially diluted with uninfected CD8 + T cell-depleted PBMCs, and added to TZM-bl cells. Each independent experiment was carried out in quadruplicate. β-gal activity was measured 48 h later. The RLUs for the control were generated from uninfected CD8 + T cell-depleted PBMCs. Data are plotted as the mean from two independent experiments. (b) 8E5 cells were serially diluted with uninfected CD8 + T cell-depleted PBMCs and added to TZM-bl cells. Each independent experiment was carried out in quadruplicate. β-gal activity was measured 48 h later. Data are plotted as the mean from two independent experiments. (c) Different p24 amounts of wild-type (wt) HIV-1 LAI and a mutant virus containing the L289K mutation in reverse transcriptase that renders the enzyme defective were added to TZM-bl cells. β-gal activity was measured 48 h later. RLU values from control TZM-bl cells alone treated with DMSO were used as control. The assay was carried out once, and the data are shown as a mean of three technical replicates. Table 2 ). The mechanisms responsible for the observed decrease in the frequency of HIV-1 DNA/10 6 cells after T cell activation are unclear, but they might be due to the cytopathic effect of the virus produced by infected, activated CD4 + T cells. Next, we added serially diluted rCD4 + T cells to 3-6 × 10 4 TZM-bl cells in a 96-well plate, and after 48 h of co-culture, we quantified β-gal expression. As a control, anti-CD3/CD28 mAb-treated rCD4 + T cells from healthy donors without HIV-1 infection were similarly co-incubated with TZM-bl cells, and expression of β-gal was measured. Infectious units per million (IUPM) cells ranged from 1.2 to 141.7 (mean 46.9; n = 13) for the TZA (Fig. 3b and Table 1 ). The IUPM values calculated for rCD4 + T cells from the same participants using the Q-VOA ranged from 0.28 to 2.37 (mean 0.70; n = 12) (Fig. 3b and Table 1 ), which is almost 70-fold lower (P = 0.006). In this study, the IUPM values calculated from the Q-VOA (0.28-2.37) were similar to previously reported values (0.03-3.00) 3 . In a subset of nine participants, we also determined the fractional provirus expression (fPVE) that could be reactivated to produce infectious virus in both assays, as described previously 18 . The fPVE provides an estimate of the size of the replication-competent viral reservoir. The fPVE calculated from the TZA (mean 4.03%; range 0.12-13.93%) was 28-fold higher (P = 0.001) than that from the Q-VOA (mean 0.14%; range 0.02-0.9%) (Fig. 3c) . We found a weak correlation that was not significant between total HIV-1 DNA/10 6 rCD4 + T cells and the IUPM calculated from the TZA (r = 0.7; P = 0.06) (Fig. 3d) . In our data set, there was no correlation between HIV-1 DNA/10 6 rCD4 + T cells, HIV-1 gag-pol RNA-positive CD4 + T cells /10 6 rCD4 + T cells, and the IUPM calculated from the Q-VOA, or between the TZA and Q-VOA assays (Fig. 3e-g ).
Further characterization of the TZA In control experiments, we exposed TZM-bl cells to efavirenz before adding activated rCD4 + T cells, which would block active HIV-1 replication while enabling us to ascertain whether cytokines released from the activated rCD4 + T cells increased TZM-bl cell β-gal activity. In rCD4 + T cells from two participants with HIV-1 infection, we observed that the IUPM values decreased from 81 and 26, respectively, in the absence of inhibitor to undetectable levels in the presence of inhibitor. This finding suggests that the higher IUPM values determined using the TZA (as compared to the Q-VOA) are not due to cytokines released after T cell activation with the anti-CD3/CD28 mAbs. We also compared our bulk rCD4 + T cell stimulation approach (Fig. 3a) to one in which we first serially diluted the rCD4 + T cells before adding anti-CD3/CD28 mAbs. The latter approach is used in the Q-VOA. We found no notable difference in the IUPM values when using these two different approaches with rCD4 + T cells isolated from three different participants with HIV-1 infection (Supplementary Fig. 2 ). Finally, we evaluated whether a positive IUPM in the TZA reflected productive HIV-1 replication. As discussed above in 'Sensitivity of TZM-bl cells to infection by replication-competent HIV-1' (Fig. 1e) , the β-gal activity for the detection of HIV-1 BaL infection in TZM-bl cells was sensitive down to a TCID 50 of 10 −2 , whereas virus production measured 10 d postinfection was sensitive only down to a TCID 50 of 1. The β-gal relative light unit (RLU) values determined from the rCD4 + T cells from the 15 participants with HIV-1 infection included in this study ranged from 1.7 × 10 6 to 4.2 × 10 6 (Fig. 1e) . In this regard, if we evaluate rCD4 + T cells from participants with HIV-1 infection who have a low RLU value, we cannot reproducibly detect extracellular virion-associated RNA following 10 d of co-culture of the TZM-bl cells with freshly added CD8 + T cell-depleted PBMCs. However, we can readily detect virus production at day 3 and day 10 after infection from rCD4 + T cells that were derived from participants with HIV-1 infection and yielded higher RLU values (Supplementary Table 3) .
DISCUSSION
There is a critical need for the development of sensitive assays that can accurately quantify inducible, replication-competent latent HIV-1.
In this study, we developed a reporter cell-based assay, TZA, to quantify inducible, replication-competent latent HIV-1 in blood. In this regard, control experiments revealed that the TZA is insensitive to virus particles defective in env or reverse transcriptase, and that β-gal 8 using the tat/rev-induced limiting dilution assay. Furthermore, our IUPM values are in line with the observation that the Q-VOA underestimates the amount of replication-competent virus by 60-fold, as compared to the level of intact proviruses estimated by sequence analysis 9 . There are, however, several differences between the TZA and Q-VOA that might contribute toward some of the differences in IUPM values noted in this study. Specifically, the Q-VOA and TZA use different measures of replication-competent HIV-1: the Q-VOA employs multiple rounds of infection and direct quantitation of extracellular virion-associated HIV-1 RNA, whereas the TZA is based on a single round of infection and quantitation of tat-induced activation of β-gal activity. There might be some virus particles that can efficiently undergo a single cycle of replication but are not capable of undergoing multiple rounds of infection. In this regard, full-length genome sequencing of virus particles produced in the TZM-bl cells may provide insight into the frequency of detecting partially attenuated replication-competent viruses in the TZA. The TZA has several advantages in that it (i) is sensitive; (ii) requires only a small blood volume (2 × 10 6 rCD4 + cells); (iii) is fast (7 d, as compared to 14 d for the Q-VOA), less labor intensive, and less expensive ($350 per assay relative to more than $1,000 for the Q-VOA) 19 . These features may allow the TZA to be used for in vitro screening to identify latency-reversing agents, as well as in clinical HIV-1-eradication studies, although the latter will necessitate further validation of the assay. Because of its low cell requirement, the TZA may also be useful for the quantification of replication-competent HIV-1 in the pediatric population, as well as in tissue.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
